SCHEMBL7753399

SCHEMBL7753399

COc1cccc(OC)c1C(=O)c1sc(Nc2ccccc2)nc1N

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.72
KMT2A Q03164 4/20 0.72
CDK5 Q00535 9/20 0.69
CDK5R1 Q15078 9/20 0.69
MAPT P10636 3/20 0.69
LMNA P02545 2/20 0.69
CCNA2 P20248 7/20 0.69
CDK2 P24941 7/20 0.69
NPC1 O15118 4/20 0.65
RAB9A P51151 2/20 0.65
GSK3B P49841 2/20 0.65
GSK3A P49840 1/20 0.65
MAPK14 Q16539 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
TUBB8B A6NNZ2 1/20 0.59
TUBB4A P04350 1/20 0.59
TUBB P07437 1/20 0.59
TUBB4B P68371 1/20 0.59
TUBB3 Q13509 1/20 0.59
TUBB2A Q13885 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1251102 0.88 CDK5 (0.85) MEN1KMT2ACDK5CDK5R1MAPT
SCHEMBL4477198 0.84 MEN1 (1.00) MEN1KMT2ACDK5CDK5R1MAPT
SCHEMBL1250849 0.82 CDK5 (1.00) MEN1KMT2ACDK5CDK5R1MAPT
SCHEMBL7756986 0.82 CDK5 (0.71) MEN1KMT2ACDK5CDK5R1MAPT
SCHEMBL1250613 0.81 CCNA2 (0.70) MEN1KMT2ACDK5CDK5R1MAPT
SCHEMBL1250645 0.81 CDK2 (0.72) MEN1KMT2ACDK5CDK5R1MAPT
SCHEMBL1250778 0.81 CCNA2 (1.00) MEN1KMT2ACDK5CDK5R1MAPT
SCHEMBL4468574 0.81 NPC1 (0.72) MEN1KMT2ACDK5CDK5R1MAPT
SCHEMBL7756961 0.80 CCNT1 (0.67) MEN1KMT2ACDK5CDK5R1MAPT
SCHEMBL163591 0.80 CDK5 (0.91) MEN1KMT2ACDK5CDK5R1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010039275-A1 Use of 2,4-diaminothiazole derivatives NOVO NORDISK A/S (DK) 2001-11-08 US disclosed
WO-2001056567-A1 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS NOVO NORDISK A/S (DK) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039275-A1 Use of 2,4-diaminothiazole derivatives GSK3A, GSK3B, GSKIP MEN1 3396/4885KMT2A 1476/4885CDK5 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.